Liproxstatin-1: Potent Ferroptosis Inhibitor with IC50 22 nM for Ferroptosis Research

Executive Summary: Liproxstatin-1 (CAS 950455-15-9) is a highly potent ferroptosis inhibitor with an IC50 of approximately 22 nM in inhibiting ferroptosis in cellular models [APExBIO]. It blocks lipid peroxidation, preventing iron-dependent cell death, especially in GPX4-deficient systems. Liproxstatin-1 has demonstrated efficacy in animal models, including protection against renal and hepatic tissue injury. The compound is insoluble in water but soluble in DMSO and ethanol under defined conditions. Storage and handling parameters are critical for maintaining its stability and reproducibility in research applications [Yu et al., 2025].

Biological Rationale

Ferroptosis is a regulated cell death pathway distinct from apoptosis and necrosis. It is characterized by the accumulation of lipid peroxides and is strictly dependent on iron homeostasis [Yu et al., 2025]. Ferroptosis is implicated in various disease models, including kidney injury, hepatic ischemia/reperfusion, and neurodegenerative diseases. Glutathione peroxidase 4 (GPX4) is a key enzyme that neutralizes lipid peroxides. GPX4-deficient cells are hypersensitive to ferroptosis. Inhibitors of ferroptosis, such as Liproxstatin-1, are essential for dissecting the role of this pathway in health and disease. They enable researchers to specifically modulate iron-dependent cell death and clarify its contribution to pathology [Related: Advanced Experimental Workflows].

Mechanism of Action of Liproxstatin-1

Liproxstatin-1 acts by preventing the accumulation of lipid peroxides, which are central mediators of ferroptotic cell death. The compound directly inhibits ferroptosis induced by agents such as RSL3, particularly in the context of GPX4 deficiency. Mechanistically, Liproxstatin-1 does not chelate iron but instead intercepts lipid peroxyl radicals, halting the peroxidation chain reaction within cellular membranes [Yu et al., 2025]. This mechanism distinguishes Liproxstatin-1 from classical antioxidants and iron chelators. Its high selectivity ensures minimal off-target effects on other cell death pathways.

Evidence & Benchmarks

• Liproxstatin-1 inhibits ferroptosis in cell-based assays with an IC50 of approximately 22 nM, as measured in GPX4-deficient cell lines (APExBIO, product page).
• It prevents lipid peroxidation induced by RSL3 and similar ferroptosis inducers, as quantified via malondialdehyde (MDA) and C11-BODIPY fluorescence assays (Yu et al., 2025).
• Liproxstatin-1 prolongs survival in mice with conditional kidney-specific Gpx4 deletion, indicating robust in vivo efficacy (Yu et al., 2025).
• The compound reduces tissue damage in hepatic ischemia/reperfusion injury models, as assessed by histology and biomarker analysis (Yu et al., 2025).
• Liproxstatin-1 is insoluble in water but solubilizes at ≥10.5 mg/mL in DMSO and ≥2.39 mg/mL in ethanol under gentle warming and sonication (APExBIO, B4987 datasheet).

Applications, Limits & Misconceptions

Liproxstatin-1 is widely used to dissect ferroptosis in cellular and animal models. It is especially valuable in studies involving GPX4 knockout or deficiency, where susceptibility to ferroptosis is heightened. The compound is also a tool for probing iron-dependent lipid peroxidation in organ injury and oncology research [Contrast: Mechanistic Clarity in Iron-Dependent Cell Death]. However, certain boundaries must be recognized.

Common Pitfalls or Misconceptions

• Not a Universal ROS Inhibitor: Liproxstatin-1 selectively blocks lipid peroxidation but does not suppress all reactive oxygen species (ROS)-mediated cell death.
• Insolubility in Water: Attempting to dissolve Liproxstatin-1 in aqueous buffers leads to precipitation and loss of activity.
• No Direct Iron Chelation: The compound does not chelate iron and thus cannot be substituted for iron chelators in experimental designs.
• Short-Term Solution Stability: Solubilized Liproxstatin-1 should be used promptly; prolonged storage of stock solutions at room temperature leads to degradation.
• Not Effective in Iron-Independent Death Pathways: Liproxstatin-1 has no effect on apoptosis, pyroptosis, or cuproptosis unless ferroptotic mechanisms are specifically engaged.

Workflow Integration & Parameters

For optimal results, Liproxstatin-1 from APExBIO (SKU B4987) should be stored at -20°C in a desiccated environment. Fresh DMSO or ethanol solutions should be prepared at ≥10.5 mg/mL or ≥2.39 mg/mL, respectively, using gentle warming and ultrasonic treatment. Solutions must be used within hours of preparation to maintain compound integrity. Typical working concentrations in cell culture range from 10 nM to 1 μM, with 22 nM being the empirically determined IC50 in GPX4-deficient cells. Always include vehicle controls and replicate wells to ensure reproducibility [Extension: Reproducible Ferroptosis Assays]. For in vivo studies, dosing regimens should be optimized based on specific model pharmacokinetics and tissue distribution.

Conclusion & Outlook

Liproxstatin-1 represents a gold-standard tool for the selective inhibition of ferroptosis. Its nanomolar potency, selectivity for lipid peroxidation, and demonstrated efficacy in both cellular and animal models define its value in elucidating iron-dependent cell death pathways. As research advances, Liproxstatin-1 will continue to underpin mechanistic studies in renal, hepatic, and emerging oncological contexts, while remaining indispensable for GPX4-deficient and injury models. For detailed protocols and troubleshooting, refer to the official APExBIO Liproxstatin-1 product page.